The versatility of macrophage heterogeneity in liver fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a highly conserved wound healing response to liver injury, characterized by excessive deposition of extracellular matrix (ECM) in the liver which might lead to loss of normal functions. In most cases, many types of insult could damage hepatic parenchymal cells like hepatocytes and/or cholangiocytes, and persistent injury might lead to initiation of fibrosis. This process is accompanied by amplified inflammatory responses, with immune cells especially macrophages recruited to the site of injury and activated, in order to orchestrate the process of wound healing and tissue repair. In the liver, both resident macrophages and recruited macrophages could activate interstitial cells which are responsible for ECM synthesis by producing a variety of cytokines and chemokines, modulate local microenvironment, and participate in the regulation of fibrosis. In this review, we will focus on the main pathological characteristics of liver fibrosis, as well as the heterogeneity on origin, polarization and functions of hepatic macrophages in the setting of liver fibrosis and their underlying mechanisms, which opens new perspectives for the treatment of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 1×
“Therefore, excessive ECM is degraded by matrix metalloproteinases (MMPs), and macrophages contribute to the reversal of fibrosis by phagocytizing ECM fragments and inhibiting the expression of tissue inhibitors of MMPs (TIMPs) (23, 24).”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Tissue-Resident Macrophage Ontogeny and Homeostasis
Ginhoux, F., & Guilliams, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.024 · Cited by 1,884 · cited 1×
“Monocytes unlikely contribute to adult macrophages pool in steady state, and KCs usually maintain through self-renewal (31).”
BackgroundResolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · cited 1×
“More importantly, the SAM subsets are conserved across species, suggesting Trem2CD9 SAMs might be a potential pathology biomarker related with hepatic fibrogenesis (63).”
BackgroundSingle cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552 · cited 1×
“However, with single cell sequencing technology, recent researches indicated that there appear to be two subsets of KCs with distinct functions in human liver, one of which support tolerogenic immune responses, while the other show pro-inflammatory phenotype (32).”
BackgroundFibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 1×
“A series of cellular and molecular responses could cause pathological changes including death of parenchymal cells and deposition of ECM in the liver (1).”
BackgroundType 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055 · cited 1×
“In addition, small molecules generated by injury release into the blood, which further attract phagocytic cells, promote their phagocytosis abilities to fulfill the removal of cellular debris and harmful substances in the tissue caused by injury (10).”
BackgroundTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 2×
“Clearance of Ly6C macrophages hinders the resolution of liver fibrosis (50).”
BackgroundSpatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Guilliams, M., Bonnardel, J., Haest, B., Vanderborght, B., Wagner, C., Remmerie, A., Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.018 · Cited by 985
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906
Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695 · cited 20×
“On the other hands, KCs could also express many types of MMPs such as MMP9, MMP12 and MMP13 to promote degradation of ECM and contribute to the resolution of fibrosis (50, 51).”
BackgroundInfluentialBonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C. L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S. A., Kremer, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.017 · Cited by 631 · cited 1×
“Therefore, signals from the tissue microenvironment could shape the identity of macrophages migrating to the liver to acquire tissue-specific phenotypes (43, 44).”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 2×
“Frontiers in Immunology 05 maintain the survival of activated HSCs through nuclear factors kB (NF-kB) signaling pathway, which aggravates liver fibrosis (58).”
BackgroundBaeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609
Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.004 · Cited by 592 · cited 1×
“Based on CITE-seq data, other nonKC macrophage subsets were identified, namely GPNMBSPP1 lipid-associated macrophages (LAMs), GPNMB bile duct LAMs, CD207CX3CR1 liver capsular macrophages (LCMs), as well as transitioning monocytes (28, 38, 39).”
MethodJu, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
Wang, J., & Kubes, P. (2016) · Cell · doi:10.1016/j.cell.2016.03.009 · Cited by 537
Sakai, M., Troutman, T. D., Seidman, J. S., Ouyang, Z., Spann, N. J., Abe, Y., Ego, K. M., Bruni, C. M., Deng, Z., Schlachetzki, J. C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.002 · Cited by 418
MeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and Fibrosis
Mann, J., Chu, D. C. K., Maxwell, A., Oakley, F., Zhu, N., Tsukamoto, H., & Mann, D. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.002 · Cited by 397 · cited 4×
“Further studies have found that the transcription of PPAR-g in HBV patients was inhibited, and might possibly be related to DNA methylation (67).”
BackgroundInfluentialThomas, J. A., Pope, C., Wojtacha, D., Robson, A. J., Gordon-Walker, T. T., Hartland, S., Ramachandran, P., Van Deemter, M., Hume, D. A., Iredale, J. P., et al. (2011) · Hepatology · doi:10.1002/hep.24315 · Cited by 346
Mossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325 · cited 2×
“Moreover, Cenicriviroc trial has excellent safety profile tested by clinical trials, suggesting that inhibition of monocyte recruitment will not affect the antimicrobial defense and immune responses of hepatic macrophages (92, 93).”
BackgroundLefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323 · cited 1×
“Moreover, Cenicriviroc trial has excellent safety profile tested by clinical trials, suggesting that inhibition of monocyte recruitment will not affect the antimicrobial defense and immune responses of hepatic macrophages (92, 93).”
BackgroundBharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
A positive feedback loop between RIP3 and JNK controls non‐alcoholic steatohepatitis
Gautheron, J., Vucur, M., Reisinger, F., Cardenas, D. V., Roderburg, C., Koppe, C., Kreggenwinkel, K., Schneider, A. T., Bartneck, M., Neumann, U. P., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403856 · Cited by 314
Lefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310 · cited 1×
“represent attractive candidates for the treatment of hepatic fibrosis, and inhibition of PPARs is closely related to sustained inflammatory state and delayed resolution of fibrosis (69).”
BackgroundLiver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Ma, P.-F., Gao, C.-C., Yi, J., Zhao, J.-L., Liang, S.-Q., Zhao, Y., Ye, Y.-C., Bai, J., Zheng, Q.-J., Dou, K.-F., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.022 · Cited by 284 · cited 1×
“Compared with unpolarized macrophages, we found that M1 macrophages are more qualified to alleviate liver fibrosis through modulating the microenvironment, suggesting that more defined macrophages will enable adoptive cell therapy more precisely for human liver fibrosis in the future (103, 104).”
BackgroundSelf-citationCCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis
Ehling, J., Bartneck, M., Wei, X., Gremse, F., Fech, V., Möckel, D., Baeck, C., Hittatiya, K., Eulberg, D., Luedde, T., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306294 · Cited by 273 · cited 1×
“Knockout of CCR2 or inhibition of CCL2 could alleviate liver fibrosis, indicating that Ly6C monocytes/ macrophages are pro-fibrotic cells and play roles in aggravating tissue damage (55, 56).”
BackgroundKarlmark, K. R., Zimmermann, H. W., Roderburg, C., Gassler, N., Wasmuth, H. E., Luedde, T., Trautwein, C., & Tacke, F. (2010) · Hepatology · doi:10.1002/hep.23894 · Cited by 249 · cited 1×
“Interestingly, Ly6C macrophages express low levels of pro-inflammatory cytokines and chemokines, while their expression of anti-inflammatory cytokines such as CX3CR1, IL-10 and arginase 1 is enhanced (60, 61).”
BackgroundA subset of Kupffer cells regulates metabolism through the expression of CD36
Blériot, C., Barreby, E., Dunsmore, G., Ballaire, R., Chakarov, S., Ficht, X., De Simone, G., Andreata, F., Fumagalli, V., Guo, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.006 · Cited by 236 · cited 1×
“And this minor subset of KCs are equipped with enriched IL-2 sensing machinery and antigen presentation capacity (33, 34).”
BackgroundModulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition
Kluwe, J., Pradere, J., Gwak, G., Mencin, A., De Minicis, S., Österreicher, C. H., Colmenero, J., Bataller, R., & Schwabe, R. F. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.015 · Cited by 217
Aoyama, T., Inokuchi, S., Brenner, D. A., & Seki, E. (2010) · Hepatology · doi:10.1002/hep.23795 · Cited by 211 · cited 1×
“Interestingly, Ly6C macrophages express low levels of pro-inflammatory cytokines and chemokines, while their expression of anti-inflammatory cytokines such as CX3CR1, IL-10 and arginase 1 is enhanced (60, 61).”
BackgroundSafety profile of autologous macrophage therapy for liver cirrhosis
Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0599-8 · Cited by 202
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189 · cited 1×
“During fibrosis progression, fibroblasts and myofibroblasts are considered as the main effector cells, which play a role in promoting the synthesis of ECM, upregulating pro-inflammatory cytokines, chemokines and angiogenesis related cytokines, while aggravating the impairment of hepatocytes and cholangiocytes (11, 12).”
BackgroundThe perivascular origin of pathological fibroblasts
Di Carlo, S. E., & Peduto, L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93558 · Cited by 164 · cited 1×
“Besides, epithelial and endothelial cells could also obtain the phenotype of myofibroblasts through activation, transformation, proliferation, infiltration, epithelial-mesenchymal transformation, mesenchymal transformation and endothelial-mesenchymal transformation (13).”
BackgroundJeong, W.-I., Park, O., Suh, Y.-G., Byun, J.-S., Park, S.-Y., Choi, E., Kim, J.-K., Ko, H., Wang, H., Miller, A. M., et al. (2011) · Hepatology · doi:10.1002/hep.24190 · Cited by 142
Bartneck, M., Scheyda, K. M., Warzecha, K. T., Rizzo, L. Y., Hittatiya, K., Luedde, T., Storm, G., Trautwein, C., Lammers, T., & Tacke, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.030 · Cited by 141
Bansal, R., van Baarlen, J., Storm, G., & Prakash, J. (2015) · Scientific Reports · doi:10.1038/srep18272 · Cited by 107 · cited 1×
“Meanwhile, the expression of anti-inflammatory genes expression is upregulated, which contributes to alleviated liver fibrosis (82).”
BackgroundHepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis
Zhou, J.-E., Sun, L., Liu, L., Jia, Y., Han, Y., Shao, J., Wang, J., Wang, Y., Yu, L., & Yan, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.038 · Cited by 104 · cited 1×
“For example, it is reported that utilizing siRNA against mannose-modified HMGB1 in hepatic macrophages could reduce inflammation and restore liver functions in a NASH mouse model (107).”
BackgroundGao, J., Wei, B., Liu, M., Hirsova, P., Sehrawat, T. S., Cao, S., Hu, X., Xue, F., Yaqoob, U., Kang, N., et al. (2021) · Hepatology · doi:10.1002/hep.31617 · Cited by 100 · cited 1×
“CCL2-CCR2 pathway is essential for the recruitment of Ly6C monocytes (54).”
BackgroundHe, F., Guo, F., Li, Z., Yu, H., Ma, P., Zhao, J., Feng, L., Li, W., Liu, X., Qin, H., et al. (2015) · Hepatology · doi:10.1002/hep.27394 · Cited by 54 · cited 1×
“When RBP-J gene is conditionally knocked out in myeloid cells, the expression of CYLD is up-regulated, and NF-kB activity and the expression of TGFb and PDGFb is inhibited, which alleviated the progression of liver fibrosis (80).”
BackgroundSelf-citation
Cited by
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
“Liver fibrosis, which results from an inappropriate response to liver injury’s wound-healing process, is a pathological condition [4,5], and the main pathological characteristics are the excessive accumulation of extracellular matrix (ECM) proteins and the loss of the normal structure of the liver tissue [6–8].”
BackgroundNovel regulators of hepatic macrophages in liver fibrosis
Tang, X., Bai, M., Du, X., Wang, H., Liu, M., Fu, X., Zhang, H., Liang, S., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705503 · Cited by 12
Jung, H., Kyun, M.-L., Kwon, J.-I., Kim, J., Kim, J.-K., Park, D., Lee, Y. B., & Moon, K.-S. (2024) · Biomaterials Science · doi:10.1039/d4bm00874j · Cited by 10
Herrera Vielma, F., Quiñones San Martin, M., Muñoz-Carrasco, N., Berrocal-Navarrete, F., Herrada, A. A., Olate-Briones, A., Zagmutt, S., Rodríguez-Rodríguez, R., González, D. R., & Zúñiga-Hernandez, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1826739 · Cited by 2
Metadata
- Authors
- Gao, C.-C., Bai, J., Han, H., & Qin, H.-Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-08-05
- Volume
- 13
- Pages
- 968879-968879
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4289860778
- Cited by
- 37
- References
- 48
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.